Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

Laurie H. Sehn; David MacDonald; Sheldon Rubin; Guy Cantin; Morel Rubinger; Bernard Lemieux; Sanraj Basi; Kevin Imrie; Randy D. Gascoyne; Jonathan Sussman; Bingshu E. Chen; Marina Djurfeldt; Lois Shepherd; Stephen Couban; Michael Crump

doi:10.1200/JCO.2010.33.6594

Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

Laurie H. Sehn, David MacDonald, Sheldon Rubin, Guy Cantin, Morel Rubinger, Bernard Lemieux, Sanraj Basi, Kevin Imrie, Randy D. Gascoyne, Jonathan Sussman, Bingshu E. Chen, Marina Djurfeldt, Lois Shepherd, Stephen Couban, Michael Crump

科研成果: 期刊稿件 › 文章 › 同行评审

29 引用（Scopus）

源语言	英语
页（从-至）	3396-3401
页数	6
期刊	Journal of Clinical Oncology
卷	29
期	25
DOI	https://doi.org/10.1200/JCO.2010.33.6594
出版状态	已出版 - 9月 1 2011
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1200/JCO.2010.33.6594

其它文件与链接

引用此

Sehn, L. H., MacDonald, D., Rubin, S., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K., Gascoyne, R. D., Sussman, J., Chen, B. E., Djurfeldt, M., Shepherd, L., Couban, S., & Crump, M. (2011). Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology, 29(25), 3396-3401. https://doi.org/10.1200/JCO.2010.33.6594

Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. / Sehn, Laurie H.; MacDonald, David; Rubin, Sheldon 等.
在: Journal of Clinical Oncology, 卷 29, 号码 25, 01.09.2011, 页码 3396-3401.

科研成果: 期刊稿件 › 文章 › 同行评审

Sehn, LH, MacDonald, D, Rubin, S, Cantin, G, Rubinger, M, Lemieux, B, Basi, S, Imrie, K, Gascoyne, RD, Sussman, J, Chen, BE, Djurfeldt, M, Shepherd, L, Couban, S & Crump, M 2011, 'Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group', Journal of Clinical Oncology, 卷 29, 号码 25, 页码 3396-3401. https://doi.org/10.1200/JCO.2010.33.6594

@article{7ad503bfb3ce40cab114bba4ae507482,

title = "Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group",

author = "Sehn, {Laurie H.} and David MacDonald and Sheldon Rubin and Guy Cantin and Morel Rubinger and Bernard Lemieux and Sanraj Basi and Kevin Imrie and Gascoyne, {Randy D.} and Jonathan Sussman and Chen, {Bingshu E.} and Marina Djurfeldt and Lois Shepherd and Stephen Couban and Michael Crump",

year = "2011",

month = sep,

day = "1",

doi = "10.1200/JCO.2010.33.6594",

language = "English",

volume = "29",

pages = "3396--3401",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "25",

}

TY - JOUR

T1 - Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma

T2 - A phase II study by the National Cancer Institute of Canada clinical trials group

AU - Sehn, Laurie H.

AU - MacDonald, David

AU - Rubin, Sheldon

AU - Cantin, Guy

AU - Rubinger, Morel

AU - Lemieux, Bernard

AU - Basi, Sanraj

AU - Imrie, Kevin

AU - Gascoyne, Randy D.

AU - Sussman, Jonathan

AU - Chen, Bingshu E.

AU - Djurfeldt, Marina

AU - Shepherd, Lois

AU - Couban, Stephen

AU - Crump, Michael

PY - 2011/9/1

Y1 - 2011/9/1

UR - http://www.scopus.com/inward/record.url?scp=80052739391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052739391&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.6594

DO - 10.1200/JCO.2010.33.6594

M3 - Article

C2 - 21810681

AN - SCOPUS:80052739391

SN - 0732-183X

VL - 29

SP - 3396

EP - 3401

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 25

ER -

Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此